Company News: Kantar Media, GlaxoSmithKline

Share this article:
Kantar announced the formation of Kantar Media, which integrates professional health-research companies PERQ/HCI and MARS Medical, as well as the former TNS Media consumer health-research divisions. The transition completes an integration process begun in 2009 when Kantar acquired TNS Media, SRDS and PERQ/HCI. On the consumer side, Kantar Media's intelligence unit provides strategic advertising and marketing information from the business unit formerly known as TNS Media Intelligence, as well as digital and social-media intelligence with Compete Cymfony and SRDS. The audiences unit integrates the unit formerly known as TNS Media Research, providing internet, TV and radio audience measurement worldwide, while the TGI & custom units measure consumer product and brand consumption, attitudes and media usage. Kantar Media's professional health side offers insight on physician media usage, as well as healthcare market intelligence and professional healthcare website audience measurement. Its other professional services include Focus/Media-Chek journal readership research; non-journal audience measurement covering digital and print media; JAR, JARScan, and MORe ad-expenditure tracking and ad-image database; MARS Medical Online web-based analysis and scheduling tool; and custom research capabilities. In October WPP acquired TNS Healthcare and combined it with Consumer Health Sciences, MattsonJack and Ziment to form KantarHealth, an amalgam of the four companies bundling global research with consulting capabilities.

GlaxoSmithKline will slash up to 4,000 sales jobs, mostly in the US and Europe, reported London's Sunday Times. The paper said the cuts, to be announced with Thursday's earnings call, come as GSK seeks to shift resources away from established markets, where growth is cooling, to emerging ones where potential is greatest.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.